Real-World Analysis Sheds Light on Bispecific Antibody Activity After CAR T in Mantle Cell Lymphoma | OncLive Real-world data suggest CD20 bispecific antibodies show activity after CD19 CAR T in mantle cell lymphoma, though durability of response remains unclear.

Many thanks to @onclive.bsky.social for reviewing our #Tandem26 abstract on outcomes of CD20 bispecifics after CD19 CAR in R/R MCL, an analysis from the CUBIC Consortium. #lymsm #tcellrx
Abstract link: www.astctjournal.org/article/S266...
www.onclive.com/view/real-wo...

Axi-cel can now be used for R/R PCNSL! HT @samyamshon.bsky.social #lymsm #tcellrx

My @mskcancercenter.bsky.social colleague Dr Roisin E. O'Cearbhaill discussing role of cell therapy at #tandem26 Joint session @astct.bsky.social @sitcancer.bsky.social #tcellrx #cartcells

CD3xCD20 BsAb CNS lymphoma #ASH25
- 28 pts from CUBIC (22 glofi), 18 active CNSi
- 6-mo PFS/OS 44%/81%
- active CNSi: ORR 56% (CR 33%)
- 67% received combo tx (BTKi, len, IT chemo)
Outcomes with active CNSi similar to trials. Need more pts & longer f/u. #lymsm #tcellrx

CNS relapse of LBCL after CAR-T #ASH25
- 1102 pts R/R LBCL: 79% CAR, 21% CIT
- 1.6% incidence of CNS relapse after CAR (2.2% CIT cohort)
- time from CAR to CNSr 4.7 mo
Corroborates known CAR CNS penetration. Upfront CAR if high CNSr risk? #lymsm #tcellrx

3-year f/u STARGLO #ASH25
- glofi-GemOx: mPFS 14 (v 3 mos), mOS 26 (v 13 mos)
- in 2L: mPFS 20 (vs 5 mos), mOS NR (vs 14 mos)
- 20% G3+ infx AEs in glofi arm
Maybe a PFS plateau on KM curves if you squint... #lymsm #tcellrx

Q-TWIST analysis of CARTITUDE-4 @surbhisidanamd.bsky.social #ASH25: 9-13 month gain of quality-adjusted time w/o symptoms/toxicity as compared to SOC, and this includes time with high-grade ICANS. #mmsm #tcellrx

Right on the eve of @ash.hematology.org #ASH25: liso-cel approved for R/R MZL after 2+ prior lines of therapy! #lymsm #tcellrx
www.fda.gov/drugs/resour...

RSV after CAR-T #ASH25
- 667 pts s/p CAR: 38 RSV infections
- 74% infx >D100 (median 8 mo)
- 71% URTI, 29% LRTI: 8 G3 cases (all got ribavirin +/- steroids/IVIG & survived)
- LRTI: older, lower ALC & CD4
Targeted vaccination strategies? #lymsm #tcellrx

Fun #ASH25 abstract: CD19 CAR in CD19-negative LBCL
- 211 pts: 18% CD19neg before CAR (all 3L+)
- no diff CRS, much less ICANS if CD19neg
- no diff CR/ORR/PFS/OS between CD19+ and CD19-
Tumor heterogeneity?! #lymsm #tcellrx

Impact of IVIG on post-CAR survival #ASH25
- 430 pts, most LBCL & axicel
- low IgA at 1 & 3 mos = increased NRM at all timepoints
- low baseline IgM = worse PFS/OS
- 20% got IVIG: no effect on NRM!
No impact of IgG on survival! Provocative & supports selective use of IVIG. #lymsm #tcellrx

Phase I/II trial of CD19 CAR in R/R CNSL #ASH25
- 45 pts, 51% PCNSL
- no G3+ CRS, 6 ICANS (only 1 G4)
- ORR 76% (CR 67%), med PFS 20 mos
Would love to know more about this product, as well as use of bridging and disease status at time of CAR infusion. #lymsm #tcellrx

Double-dose axi-cel 2L high-risk LBCL #ASH25
- 15 pts, 69% refractory, 4 couldn't get 2nd dose
- no DLTs w/i 28 days
- ORR 91% (CR 73%), 6-mo PFS 79%, 100% OS
- 3 G1 CRS/ICANS after 2nd dose
Correlative data: less CAR exhaustion & better cytotox after 2nd dose. #lymsm #tcellrx

Are you prepared to recognize & mitigate toxicities following CAR-T and other immune effector-cell therapies?

Join Drs. Nancy Berliner, Nirali Shah & moderator Dr. Kim Nichols for updates in our current understanding of HLH-like toxicities.

🔗https://ow.ly/vTwJ50XombR #HemeSky #MedSky #TcellRX

Also, significantly worse G3+ AEs with epco:
- 12% G3+ CRS epco, 2% glofi, 3 G5 CRS with epco (!!!)
- 3.2% G3+ ICANS epco, 1% glofi, 1 G5 ICANS with epco
#lymsm #tcellrx

🏋️Training Course! The Use of Cell Therapies for Autoimmune Diseases: CAR-T in #Paris Oct 16-17
#immunotherapy #autoimmune #Tcell #tcellrx @isctglobal.bsky.social
www.isctglobal.org/workforce-de...

AbbVie (ABBV) to Acquire Capstan Therapeutics for $2.1 Billion AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. ("Capstan"), a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using tLNPs, today...

🚨🚨🚨Big news for development of in vivo CAR T cells: AbbVie (ABBV) to Acquire Capstan Therapeutics for $2.1 Billion @abbvie @capstantx #TCell #tcellrx #immunotherapy www.streetinsider.com/Corporate+Ne...

No more REMS for FDA-approved CAR-T products! Also, labeling updated for only 2 weeks in proximity to CAR center and 2 weeks no driving. #lymsm #tcellrx #mmsm www.fda.gov/vaccines-blo...

Mosun in 1L FL #18ICML
- 76 pts, ORR 95%, CR 82%
- 1-yr PFS 89%, OS 99%
- CRS mostly G1, 3% req'd hospitalization for infx
- 1 death d/t COVID during tx
Looking forward to longer f/u. #lymsm #tcellrx

We stan bridging RT before CAR! #18ICML
- 116 pts with comprehensive RT to all PET avid sites
- higher RT dose = less post-CAR G3+ CRS
- higher LDH after RT = more G3+ CRS/ICANS
Who else is using multisite bridging RT before CAR? #lymsm #tcellrx

>1500 trial & @cibmtr.bsky.social pts who received liso-cel:
- 96-97% of CRS events were before D+15
- 88-95% ICANS before D+15
- no G5 CRS/ICANS after D+15
Do we really need a full 30 days of monitoring after liso-cel? #lymsm #tcellrx #18ICML

Pola bridging to CAR #18ICML
- 200 pts: 122 polaBR, rest polaR
- no diff in pre-CAR ORR with polaBR v polaR
- more heme tox with BR
- more ICANS w/ BR?
tl;dr polaR just fine for bridging. #lymsm #tcellrx

CD19 CAR in SOT PTLD #18ICML
- 12 pts, mostly kidney, most on steroids alone or nothing for IS
- mPFS/mOS both 17 mos
- all had CRS (2 Gr 3-4), 7 ICANS (2 Gr5!)
- 1 graft failure
Activity but seems toxic. No mention of product (axi-cel?) #lymsm #tcellrx

From @dgermain21.bsky.social #18ICML plenary: TEX (T exhausted) phenotype did not derive benefit from CAR-T in ZUMA-7. Super-exhausted macrophages appear to drive T-cell exhaustion in TEX. A subgroup which shouldn't get CAR? #18ICML #lymsm #tcellrx @icmlugano.bsky.social

Glofi escalated ramp-up post-CAR:
- glofi 30 mg by D8
- 46 pts, all prior CAR, 48% relapse >6 mos post CAR
- mPFS 3.8 mos, mOS 14.7 mos
- 9% G2 CRS, 2% G2 ICANS, no G3+
Accelerated ramp-up w/o additional tox. #lymsm #tcellrx
www.nature.com/articles/s43...

2nd myeloid cancers post CD19 CAR @NGazeau14
- 539 pts, all B-NHL
- 2-yr cumulative risk t-MN: 4.5% (10% at 4 yrs!)
- ⬆️ MCV & high-grade ICANS risk factors for t-MN
- 86% of t-MN had pre-CAR mutations
Important retrospective study for #tcellrx. #lymsm
buff.ly/57BGn10

📢 Clinicians and researchers! Are you researching CAR-Ts or using this therapy to treat your patients?

The CAR-T Toxicities Consortium, of which ASH is a member, is conducting a survey to improve toxicity management. Take the survey now: https://bit.ly/3FTVfpp

#TcellRX #HemeOnc #MedSky #HemeSky

IKAROS & antigen escape in B-ALL: A recent study shows that low IKAROS expression can induce CD19 & CD22 downregulation, creating escape variants when treated with single-target CAR-T therapies.

#CARTcells #TcellRx #Immunotherapy

ZUMA-12 3-year follow-up:
- 40 pts
- ORR 92%, CR 86%, mDOR NR
- 3-yr EFS 73%, OS 81%
- 80% of pts alive at cutoff (5 died d/t PD)
High EFS in high-risk subgroups, too! #lymsm #tcellrx
buff.ly/q9P62i4

Our @cuhematology.bsky.social lymphoma Dr. Kamdar was just published in @bloodportfolio.bsky.social as part of a multicenter study of CD19 CAR-T outcomes for Burkitt lymphoma. Median PFS only 2.3 months with median OS of 6 months. #lymsm #tcellrx pubmed.ncbi.nlm.nih.gov/39938007/